JP2010536714A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536714A5
JP2010536714A5 JP2010506728A JP2010506728A JP2010536714A5 JP 2010536714 A5 JP2010536714 A5 JP 2010536714A5 JP 2010506728 A JP2010506728 A JP 2010506728A JP 2010506728 A JP2010506728 A JP 2010506728A JP 2010536714 A5 JP2010536714 A5 JP 2010536714A5
Authority
JP
Japan
Prior art keywords
seq
peptide
amino acid
group
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010506728A
Other languages
English (en)
Japanese (ja)
Other versions
JP5417667B2 (ja
JP2010536714A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2008/002232 external-priority patent/WO2009028150A1/en
Publication of JP2010536714A publication Critical patent/JP2010536714A/ja
Publication of JP2010536714A5 publication Critical patent/JP2010536714A5/ja
Application granted granted Critical
Publication of JP5417667B2 publication Critical patent/JP5417667B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010506728A 2007-08-24 2008-08-19 抗原ペプチドおよび化学療法薬を用いる膵癌のための併用療法 Expired - Fee Related JP5417667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95792307P 2007-08-24 2007-08-24
US60/957,923 2007-08-24
PCT/JP2008/002232 WO2009028150A1 (en) 2007-08-24 2008-08-19 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Publications (3)

Publication Number Publication Date
JP2010536714A JP2010536714A (ja) 2010-12-02
JP2010536714A5 true JP2010536714A5 (enExample) 2011-09-29
JP5417667B2 JP5417667B2 (ja) 2014-02-19

Family

ID=40386893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506728A Expired - Fee Related JP5417667B2 (ja) 2007-08-24 2008-08-19 抗原ペプチドおよび化学療法薬を用いる膵癌のための併用療法

Country Status (19)

Country Link
US (1) US8703713B2 (enExample)
EP (1) EP2195003A4 (enExample)
JP (1) JP5417667B2 (enExample)
KR (1) KR20100047899A (enExample)
CN (1) CN101883577A (enExample)
AR (1) AR068020A1 (enExample)
AU (1) AU2008292966C1 (enExample)
BR (1) BRPI0815726A2 (enExample)
CA (1) CA2697501A1 (enExample)
IL (1) IL204143A (enExample)
MX (1) MX2010002178A (enExample)
MY (1) MY160406A (enExample)
NZ (1) NZ583578A (enExample)
RU (1) RU2472522C2 (enExample)
SG (1) SG183770A1 (enExample)
TW (1) TWI436775B (enExample)
UA (1) UA100702C2 (enExample)
WO (1) WO2009028150A1 (enExample)
ZA (1) ZA201001580B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US20080034017A1 (en) * 2006-08-04 2008-02-07 Dominic Giampaolo Links to a common item in a data structure
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
JP5904552B2 (ja) * 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
DE102013214023B4 (de) * 2013-07-17 2015-02-12 Siemens Aktiengesellschaft Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist
EP3205720B1 (en) * 2014-10-09 2019-09-11 Yamaguchi University Car expression vector and car-expressing t cells
CA2964361A1 (en) * 2014-10-14 2016-04-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Peptide-based methods for treating pancreatic cancer
EP3626260A4 (en) * 2017-05-19 2021-05-19 Keio University PEPTIDE VACCINE AND PEPTIDE VACCINE COMPOSITION FOR CRANIAL NERVOUS DISEASE
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
CA3134420A1 (en) 2019-04-12 2020-10-15 Riptide Bioscience, Inc. Methods for modulating macrophage activity
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB213645A (en) 1922-12-22 1924-03-24 Frank Lincoln Morse Improvements in and relating to chain and sprocket wheel gearing
US3265572A (en) * 1961-09-20 1966-08-09 S B Penick And Company Process for preparing tyrociding and product produced thereby
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE281469T1 (de) * 1993-03-25 2004-11-15 Merck & Co Inc Inhibitor des wachstumsfaktors für gefäss- endothelzellen
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
CA2328893A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
DK2261249T3 (en) * 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
CN1960732A (zh) * 2004-06-03 2007-05-09 霍夫曼-拉罗奇有限公司 用吉西他滨和egfr－抑制剂治疗
CN101080417B (zh) 2004-12-17 2011-01-19 伊莱利利公司 吉西他滨的酰胺前体药物、其组合物以及应用
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
MX2009008750A (es) 2007-02-16 2009-08-27 Oncotherapy Science Inc Terapia de vacuna para neovascularizacion coroidal.

Similar Documents

Publication Publication Date Title
JP2010536714A5 (enExample)
JP2006514104A5 (enExample)
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
WO2010051541A3 (en) Compositions containing delta-9-thc-amino acid esters and process of preparation
JP2004537581A5 (enExample)
IL308807B2 (en) Combination therapy for treating cancer
NZ592510A (en) HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
JP2019089773A (ja) ミトコンドリア透過性転移の阻止方法
NZ608502A (en) Polypeptides that bind to human complement component c5
JP2011511753A5 (enExample)
EP2476693A3 (en) Peptide vaccines for cancers expressing tumor-associated antigens
JP2012500001A5 (enExample)
JP2002523466A5 (enExample)
JP2012176978A5 (enExample)
JP2015510393A5 (enExample)
JP2018504901A5 (enExample)
JP2012529293A5 (enExample)
JP2018510132A5 (enExample)
JP2018512454A5 (enExample)
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
JP2014050390A5 (enExample)
JP2006506942A5 (enExample)
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
JP2004521123A5 (enExample)
JP2010513327A5 (enExample)